Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: ACAD stock price vs FICO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FICO's multiple
Needs FICO P/E.
Implied fair value · at ACAD's multiple
Needs ACAD P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ACAD FY 2025 (ended Dec 31, 2025) · FICO FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 4.63x · EV / EBITDA 32.90x
Capital structure 85% equity / 15% debt · EV / Revenue 11.78x · EV / EBITDA 25.32x
FICO carries the larger enterprise value at $23.46B against $4.96B; ACAD trades on the lower EV / Revenue multiple (4.63x vs 11.78x); FICO on the lower EV / EBITDA (25.32x vs 32.90x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
FAIR ISAAC CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.25x
-1.98x
Net debt / EBITDA
Leverage against operating earnings
0.85x
3.58x
Cash and equivalents
Liquid reserves on the balance sheet
$177.70M
$134.14M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ACAD vs SUPN
Sage Therapeutics, Inc.
ACAD vs SAGE
Jazz Pharmaceuticals plc
ACAD vs JAZZ
Alkermes plc.
ACAD vs ALKS
Harmony Biosciences Holdings, Inc.
ACAD vs HRMY
Krystal Biotech, Inc.
ACAD vs KRYS
MSCI Inc.
ACAD vs MSCI
MOODYS CORP /DE/
ACAD vs MCO
SS&C Technologies Holdings Inc
ACAD vs SSNC
Verisk Analytics, Inc.
ACAD vs VRSK
EQUIFAX INC
ACAD vs EFX
$306.51M
$3.46B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
